[18F]2-(p-methylaminophenyl)-7-(2-fluoroethoxy)imidazo[2,1-b]benzothiazole | 1240348-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [18F]2-(p-methylaminophenyl)-7-(2-fluoroethoxy)imidazo[2,1-b]benzothiazole
• 英文别名: (18F)Fibt；4-[6-(2-(18F)fluoranylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]-N-methylaniline
• CAS: 1240348-39-3
• 化学式: C₁₈H₁₆FN₃OS
• 分子量: 340.411
• InChiKey: WWPSVHYBUBUUFS-AWDFDDCISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-[4-(2-溴乙酰基)苯基)乙酰胺 在 Kryptofix222[18F]钾盐 、 三溴化硼 、 potassium carbonate 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 1.83h， 生成 [18F]2-(p-methylaminophenyl)-7-(2-fluoroethoxy)imidazo[2,1-b]benzothiazole
  参考文献：
  名称：

  A Novel ¹⁸F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques

  摘要：

  F-18-labeled imidazo[2,1-b]benzothiazole ([F-18]8) was synthesized and evaluated as a tracer for cerebral beta-amyloid deposits (A beta) by means of positron emission tomography (PET). [F-18]8 exhibits a high affinity to A beta and suitable brain uptake kinetics combined with a high metabolic stability in the brain. In a double transgenic APP/PS1 mouse model of Alzheimer's disease, we demonstrated a specific uptake of [F-18]8 in A beta-containing telencephalic brain regions. The specific binding of [F-18]8 to A beta was confirmed by regional brain biodistribution and autoradiography and correlated to immunohistochemistry staining. Analysis of brain sections of APP/PS1 mouse injected with a cocktail of [F-18]8 and reference compound [H-3]PiB revealed that the two tracers bind to A beta plaques in the brain of mouse in a comparable binding pattern. [F-18]8 represents the first high-contrast PET imaging agent for detection of A beta plaques in transgenic mouse model of Alzheimer's disease and holds promise for transfer to a clinical evaluation.

  DOI：

  10.1021/ml200123w

文献信息

• Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides
  申请人：Gjermund Henriksen

  公开号：US20120070374A1

  公开（公告）日：2012-03-22

  The invention relates to the provision of compounds, methods for producing them, and their use for imaging and quantification of aggregates of β-amyloid peptides in vivo. In a preferred aspect of the invention, a tracer is administered to humans and displays enrichment in body parts that are containing aggregates of amyloid peptides. Tracers of the invention can be used for non-invasive depiction and quantification of aggregates of β-amyloid peptides in humans affected with diseases that are characterized in the generation of such aggregates.

  本发明涉及提供化合物、制备它们的方法以及它们在体内成像和量化β-淀粉样肽聚集物的使用。在本发明的一个优选方面，向人体注射示踪剂，并在含有淀粉样肽聚集物的身体部位显示富集。本发明的示踪剂可用于非侵入性地描绘和量化患有生成此类聚集物的疾病的人体内β-淀粉样肽聚集物。
• A Novel ¹⁸F-Labeled Imidazo[2,1-<i>b</i>]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques
  作者：Behrooz H. Yousefi、Alexander Drzezga、Boris von Reutern、André Manook、Markus Schwaiger、Hans-Jürgen Wester、Gjermund Henriksen

  DOI：10.1021/ml200123w

  日期：2011.9.8

  F-18-labeled imidazo[2,1-b]benzothiazole ([F-18]8) was synthesized and evaluated as a tracer for cerebral beta-amyloid deposits (A beta) by means of positron emission tomography (PET). [F-18]8 exhibits a high affinity to A beta and suitable brain uptake kinetics combined with a high metabolic stability in the brain. In a double transgenic APP/PS1 mouse model of Alzheimer's disease, we demonstrated a specific uptake of [F-18]8 in A beta-containing telencephalic brain regions. The specific binding of [F-18]8 to A beta was confirmed by regional brain biodistribution and autoradiography and correlated to immunohistochemistry staining. Analysis of brain sections of APP/PS1 mouse injected with a cocktail of [F-18]8 and reference compound [H-3]PiB revealed that the two tracers bind to A beta plaques in the brain of mouse in a comparable binding pattern. [F-18]8 represents the first high-contrast PET imaging agent for detection of A beta plaques in transgenic mouse model of Alzheimer's disease and holds promise for transfer to a clinical evaluation.